SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying on massive volume as investors bet on the companys role in critical AI infrastructure and its potential as a key player in the optical interconnect market. The community is actively discussing the stock's significant momentum, speculation regarding potential hyperscaler partnerships, and the intense pressure on short sellers amid a tightening pool of available shares.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinear is currently trending as investors re-rate the stock as a key AI infrastructure and data center connectivity play following a significant earnings beat and bullish guidance. While community sentiment is divided between those betting on long-term momentum and skeptics who view the stock as overbought and vulnerable to a correction, many are actively tracking its role as a strategic partner to major tech players.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a high-volatility meme coin, with the community actively rallying around the developer's commitment to avoiding rug pulls through transparent token burns and manual airdrops. Investors are currently hyper-focused on the project's growth potential and upcoming charting developments, urging others to buy and hold as they aim to hit key market cap milestones.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors brace for a critical earnings week, with the community closely analyzing the impact of AI capital expenditures on future growth and forward guidance. While some traders express skepticism regarding the company's AI strategy and recent leadership transition, others remain focused on the stability of its services ecosystem and potential momentum ahead of the upcoming earnings report.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as investors aggressively rotate into semiconductor stocks following strong sector-wide sentiment, with the community actively debating whether the current momentum is a sustainable long-term re-rating or an overextended bubble primed for a pullback ahead of earnings. While many investors are expressing high conviction in the CPU-to-GPU shift and the company's long-term growth narrative, bears are citing extreme technical indicators and elevated valuations as catalysts for potential near-term volatility.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing heightened market attention and increased trading volume, with community members actively discussing potential supply-reduction burns and speculative hopes for a project revival. Despite polarized sentiment between those who view it as a high-risk long play and those dismissing it as a legacy project, proponents remain focused on decentralization efforts and prospective chain developments.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently a focus for investors as they navigate complex community debates regarding potential strategic partnerships, the impact of federal steel tariffs, and persistent concerns over debt levels. Community discussions are heavily centered on whether the company's vertically integrated domestic infrastructure will drive a long-term turnaround or if ongoing market manipulation and management decisions will continue to weigh on performance.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors digest an expanded collaboration with Synopsys, fueling speculation about potential major licensing deals ahead of upcoming earnings. Community sentiment remains polarized, with bulls tracking technical validations and partnership developments, while bears emphasize the lack of realized commercial revenue after years of speculative activity.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is seeing significant investor attention ahead of a pivotal clinical data readout for its Phase 2/3 trial of tovecimig in biliary tract cancer. The community is focused on the potential for strong secondary endpoint results, with many traders closely monitoring the setup as a high-volatility binary event.

Magnachip Semiconductor Corp. engages in the design and manufacture of analog and mixed-signal platform solutions for communications, Internet of Things (IoT), consumer, computing, industrial, and automotive applications. Its products include MOSFETs, IGBTs, AC-DC/DC-DC converters, light-emitting diode (LED) drivers, regulators, power management integrated circuits (PMICs), and industrial applications such as power suppliers, e-bikes, photovoltaic inverters, LED lighting, and motor drives. The company was founded on November 26, 2003 and is headquartered in Cheongju-si, South Korea.

MagnaChip Semiconductor Corp

MagnaChip Semiconductor is currently a focal point for investors due to intensifying speculation regarding a potential buyout or strategic sale, with the community closely tracking rumors involving key South Korean players like LX Semicon. Sentiment is further bolstered by the company's aggressive stock repurchase program, significant cash position, and a pivot toward high-growth sectors like automotive power solutions and OLED technology.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>In February 2025, Hims &amp; Hers announced the acquisition of a peptide facility in California to meet the growing demand among Americans for personalized healthcare and treatment options.</li><li>An NYT report stated that top leaders at the FDA have reservations about peptides, according to a senior Department of Health and Human Services official.</li><li>On a recent episode of the Joe Rogan podcast, Health and Human Services Secretary Robert F. Kennedy Jr., who oversees the FDA, said he is a “big fan” of peptides.</li></ul>Hims &amp; Hers Health Inc. (HIMS) shares surged on Tuesday morning amid a report stating that the U.S. Food and Drug Administration is moving to lift restrictions on peptides.According to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nytimes.com/2026/03/31/health/peptide-ban-fda-rfk-jr.html">report</a> by The New York Times, the FDA is moving to allow compounding pharmacies to manufacture over a dozen injectable peptides&nbsp;that were previously banned due to potential safety risks.This decision would reverse a 2023 ban that resulted in the removal of 14 peptides from a list of products that the FDA allowed compounding pharmacies to produce.<a href="https://stocktwits.com/symbol/HIMS">Shares of Hims &amp; Hers</a>, which provides compounded medications, surged more than 7% in Tuesday morning’s trade.<h2 class="st-heading-2">Top FDA Leaders Have Reservations About Peptides, Says Report</h2>The report added that top leaders at the FDA have reservations about peptides, according to a senior Department of Health and Human Services official. It noted that if the FDA had flagged peptides as being marketed through unproven claims of disease-fighting and cosmetic benefits.In its 2023 notification, the regulator listed several bulk drug substances, including peptides, noting that it had identified “potential significant safety risks” associated with them.<h2 class="st-heading-2">RFK Jr. Says He Is A ‘Big Fan’ Of Peptides</h2>During an episode of the Joe Rogan podcast earlier this month, Secretary of Health and Human Services Robert F. Kennedy Jr. said that he is a “big fan” of peptides. As the HHS secretary, RFK Jr. oversees the FDA.“I’ve used them myself, and used them with really good effect on a couple of injuries,” he said, while adding that during the Biden administration, 19 peptides were “illegally” moved to Category 2 of the Bulk Substances Nominated Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.This category prohibits compounding pharmacies from formulating compounds comprising peptides, RFK Jr. added.“There was huge demand for peptides and a black market came up, and the black market is run by companies that say the peptides are for animal use or research purposes. And that peptide now basically completely replaced the legal market,” he said.<h2 class="st-heading-2">Where Does Hims &amp; Hers Fit In This Case?</h2>Hims &amp; Hers had come&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">under fire</a> from regulators and Novo Nordisk AS (NVO) for offering a compounded version of the company’s best-selling weight-loss pill, Wegovy.Novo Nordisk subsequently&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">dropped</a> its lawsuit against Hims &amp; Hers and announced a partnership to offer Ozempic and Wegovy at affordable self-pay prices on the telehealth company’s platform.Earlier in February 2025, Hims &amp; Hers announced the acquisition of a peptide facility based in California to address the growing demand from Americans for personalized healthcare and treatment options.“The peptide capabilities made possible through this acquisition position the company in the coming years to explore exciting advances in peptide innovation, including across areas of consumer need such as preventive health, metabolic optimization, cognitive performance, recovery science, and biological resistance,” the company said.<h2 class="st-heading-2">What Are Peptides?</h2>Peptides are short chains of amino acids, the same building blocks that make up proteins, linked together by peptide bonds.Blockbuster weight-loss drugs Ozempic and Wegovy are also peptide medications that use glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity by&nbsp;stimulating insulin secretion.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 39% year-to-date and 33% over the past 12 months. The iShares Core S&amp;P Mid-Cap ETF (IJH) is up 14% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 22%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/warren-buffett-sold-apple-shares-too-soon-berkshire/cZEPvVFRIVi">Buffett Says He Sold Apple Shares Too Soon, But Does Not Regret It: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock Gains As FDA Reportedly Moves Toward Lifting Restrictions On Peptides

This decision would reverse a 2023 ban that resulted in the removal of 14 peptides from a list of products that the FDA allowed compounding pharmacies to produce.

Equity

<ul class="summary-bullets"><li>Wells Fargo cut Doximity’s price target to $45 from $55 while maintaining an ‘Overweight’ rating.</li><li>Piper Sandler expressed confidence in Doximity’s platform despite a bleak near-term outlook.</li><li>The&nbsp;company expects Q4 revenue in the range of $143 million to $144 million, compared to $185.1 million it reported in the third quarter.</li></ul>Shares of Doximity Inc. (DOCS) slumped 35% in premarket trading on Friday, following a series of brokerage actions amid regulatory pressures and lower-than-expected fourth-quarter revenue guidance.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/DOCS">DOCS stock </a>will fall to its lowest levels since November 2023.<h2 class="st-heading-2">Competition, Regulatory Pressure Are Key Risks</h2>Wells Fargo cut Doximity’s price target to $45 from $55 while maintaining an ‘Overweight’ rating, according to The Fly. The firm said limited visibility was already a concern ahead of the third quarter, but additional caution from pharmaceutical clients led to fewer upfront commitments and slower conversions than expected. While the stock’s decline to around $20 appears excessive, the brokerage noted that investor sentiment could take time to reboundPiper Sandler slashed the company’s price target to $40 from $70, while maintaining an ‘Overweight’ rating. Analyst Jessica Tassan noted that Doximity is off to a slow start in 2026, with weak Q2 and Q3 bookings, as market growth slowed to about 5% and sales cycles lengthened amid pharma’s macro-driven caution. Despite the bleak near-term outlook, the firm expressed confidence in Doximity’s platform's strength.Needham analyst Scott Berg lowered Doximity’s price target to $55 from $75 while maintaining a ‘Buy’ rating, citing competition and regulatory pressures as key risks even if the sell-off appears overdone. Although the Q4 guidance is disappointing, Needham expects budgets to improve through 2026.<h2 class="st-heading-2">Client Uncertainty Around Policy Changes</h2>In a call with analysts on Thursday, Doximity stated that client uncertainty around recent policy changes and the Most Favored Nation agreement affected its annual budgets.“First, we saw multiple customers deploy a lower percentage of their annual budgets upfront than usual as 2026 planning wasn't fully complete and some funds remained unreleased,” said Timothy Cabral, a member of the board.“Second, this uncertainty resulted in many deals we normally have signed by December 31 being delayed and pushed into our fiscal Q4. This is evident in our January pharma bookings growth rate, which is the best we've seen since going public,” Cabral added.Doximity’s Q3 revenue grew 10% to $185.1 million, but its diluted earnings per share declined to $0.31 from $0.37. The company expects Q4 revenue in the range of $143 million to $144 million and FY 2026 revenue between $642.5 million and $643.5 million. The company also announced a share repurchase program of up to $500 million of its Class A common stock.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market crash, retail sentiment flipped to “extremely bullish” from “bearish” over the past 24 hours, amid “extremely high” message volumes.<img src="https://news.stocktwits-cdn.com/DOCS_jpg_2d9473084f.webp" alt="DOCS.jpg">Users felt that the selloff was an “overreaction”.<stembedurl>https://stocktwits.com/Noisy/message/644244636</stembedurl><stembedurl>https://stocktwits.com/giuseppe8469/message/644205757</stembedurl>Over the past year, the stock has declined by around 43%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/amzn-stock-falls-below-long-term-moving-average-slumps-premarket/cZbFfDJR4nC">AMZN Stock Falls To 8-Month Lows In Pre-Market After Declining Below 200-DMA For First Time Since October</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

Why Did DOCS Stock Plunge 35% In Pre-Market Today?

Multiple brokerages cut their price target on the stock after Doximity reported a fall in third-quarter earnings and a soft fourth-quarter revenue outlook.

Shares of Teladoc Health Inc. surged as much as 3% on Tuesday morning, peaking at levels last seen a week ago before trimming some gains later in the day.&nbsp;The rise followed an announcement of a new collaboration with Amazon.com, aimed at expanding access to Teladoc’s programs, including those for diabetes, hypertension, pre-diabetes, and weight management, through Amazon’s Health Benefits Connector.&nbsp;No further details about the collaboration’s terms were provided.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TDOC_sentiment_and_message_volume_Jan_14_736f372c12.png" alt="TDOC sentiment and message volume Jan 14.png" width="1318" height="324"><figcaption>TDOC sentiment and message volume Jan 14 as of 10:20 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment shifted dramatically to ‘extremely bullish’ from ‘bearish’ a day ago, with message volume hitting its highest levels in the past month.&nbsp;Some retail investors expressed optimism, with one speculating that this partnership could pave the way for an acquisition by Amazon, which has been expanding its presence in telehealth services.<stembedurl>https://stocktwits.com/rxptgh/message/599945090</stembedurl><stembedurl>https://stocktwits.com/Genuisboltz/message/599941043</stembedurl><stembedurl>https://stocktwits.com/Genuisboltz/message/599941043</stembedurl>Since 2018, Amazon has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slides-after-amazon-medical-one-rival-service/cJ4Z1asRfj">steadily</a> built out its healthcare offerings, which now include Amazon Care (a hybrid virtual and in-person care service) and One Medical (a telehealth platform providing pay-per-visit care and membership options).&nbsp;The new collaboration builds on Teladoc and Amazon’s partnership that began in 2022 to provide virtual care through Alexa devices.Teladoc, which experienced rapid growth during the COVID-19 pandemic, has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/teladoc-falls-withdraws-financial-outlook-retail-bearish/c7HhdmtRRR">struggled</a> to maintain that momentum in the face of rising competition and poor financial performance.&nbsp;Following the ouster of CEO Jason Gorevic last year, the company has been trying to chart a recovery path.&nbsp;Despite the recent gains, its stock remains 97% off its all-time high during the pandemic.&nbsp;With a current short interest of 13.2%, Teladoc has gained just over 3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, a Teladoc logo is seen on a smartphone screen and in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Teladoc’s New Amazon Tie-Up Sparks Retail Sentiment Surge Even As Stock Swings Wildly

Following the ouster of CEO Jason Gorevic last year, the telehealth company has been trying to chart a recovery path.

EDOC
Global X Funds - Global X Telemedicine & Digital Health ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest EDOC News

EDOCGlobal X Funds - Global X Telemedicine & Digital Health ETF